Patents Assigned to Zentaris AG
  • Patent number: 7378522
    Abstract: The invention relates to new quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone.
    Type: Grant
    Filed: July 23, 2004
    Date of Patent: May 27, 2008
    Assignee: Zentaris AG
    Inventors: Peter Strehlke, Peter Droescher, Ulrich Buehmann, Norbert Schmees, Peter Muhn, Holger Hess-Stumpp, Roland Kühne, Eckhard Guenther, Emmanuel Polymeropoulos, Antonius M. Ter Laak
  • Patent number: 7122570
    Abstract: This invention provides new tetrahydrocarbazole derivatives that act as ligands for G-protein-coupled receptors (GPCR), especially as antagonists of the gonadotropin-releasing hormone (GnRH). A pharmaceutical composition that contains these new tetrahydrocarbazole derivatives as well as a process for the production of the new tetrahydrocarbazole derivatives are also provided. Moreover, this invention relates to the administration of tetrahydrocarbazole derivatives for treating pathologic conditions that are mediated by GPCR, especially for inhibiting GnRH, in mammals, especially humans, who require such an administration, as well as the use of tetrahydrocarbazole derivatives for the production of a pharmaceutical agent for treating GPCR-mediated pathologic conditions, especially for inhibiting GnRH.
    Type: Grant
    Filed: December 16, 2002
    Date of Patent: October 17, 2006
    Assignee: Zentaris AG
    Inventors: Marcus Karl Koppitz, Hans Peter Muhn, Kenneth Jay Shaw, Holger Hess-Stump, Klaus Paulini
  • Patent number: 6890926
    Abstract: The invention relates to novel quinoline derivatives of the formula 1, to their preparation and to their use as medicaments, in particular for treating tumors.
    Type: Grant
    Filed: July 20, 2001
    Date of Patent: May 10, 2005
    Assignee: Zentaris AG
    Inventors: Peter Emig, Eckhard Günther, Jürgen Schmidt, Bernd Nickel, Bernhard Kutscher
  • Patent number: 6863891
    Abstract: A novel lyophilizate and method of preparation as well as the use of the lyophilizate to treat female infertility and for gonad protection. Cetrorelix is dissolved in acetic acid 30% v/v, the solution is transferred to water and freeze dried.
    Type: Grant
    Filed: January 9, 2002
    Date of Patent: March 8, 2005
    Assignee: Zentaris AG
    Inventors: Jürgen Engel, Burkhard Wichert, Dieter Sauerbier, Thomas Reissmann
  • Patent number: 6861409
    Abstract: The invention relates to compounds of formula I which are useful for elevating the plasma level of growth hormone in a mammal as well for the treatment of growth hormone secretion deficiency, growth retardation in child and metabolic disorders associated with growth hormone secretion deficiency.
    Type: Grant
    Filed: June 13, 2001
    Date of Patent: March 1, 2005
    Assignee: Zentaris AG
    Inventors: Jean Martinez, Jean-Alain Fehrentz, Vincent Guerlavais
  • Patent number: 6849715
    Abstract: A method of treating a disorder characterized by an activating mutation in a Ras proto-oncogene, comprising contacting cells of a patient suffering from the disorder with a protein having the toxic activity of Clostridium sordellii toxin LT under conditions favoring inactivation of Ras by glucosylation of Ras' threonine 35 in said cell. The protein preferably is an immunotoxin that contains as a toxic domain the catalytic domain of toxin LT.
    Type: Grant
    Filed: July 31, 1998
    Date of Patent: February 1, 2005
    Assignee: Zentaris AG
    Inventors: Christoph Von Eichel-Streiber, Patrice Boquet, Monica Thelestam
  • Publication number: 20040229823
    Abstract: The invention relates to compounds of formula I 1
    Type: Application
    Filed: May 4, 2004
    Publication date: November 18, 2004
    Applicant: Zentaris AG
    Inventors: Jean Martinez, Jean-Alain Fehrentz, Vincent Guerlavais
  • Patent number: 6812243
    Abstract: The invention relates to tyrosine kinase inhibitors of the bis-indolyl compound type of the general formula I: pharmaceuticals containing them and their use for the treatment of malignant and other diseases based on pathological cell proliferation.
    Type: Grant
    Filed: May 3, 2002
    Date of Patent: November 2, 2004
    Assignee: Zentaris AG
    Inventors: Siavosh Mahboobi, Sabine Kuhr, Herwig Pongratz, Alfred Popp, Harald Hufsky, Frank-D Bohmer, Steffen Teller, Andrea Uecker, Thomas Beckers
  • Patent number: 6790858
    Abstract: The present invention relates to a compound of formula (I): where R1-R6, W, X, and Y are defined herein, a composition includung the compound of formula (I), and a method for, e.g., male birth control, including administering an effective amount of a compound of formula (I) to a patient in need thereof.
    Type: Grant
    Filed: February 21, 2002
    Date of Patent: September 14, 2004
    Assignee: Zentaris AG
    Inventors: Peter Strehlke, Peter Droescher, Ulrich Buehmann, Norbert Schmees, Peter Muhn, Holger Hess-Stumpp, Roland Kühne, Eckhard Guenther, Emmanuel Polymeropoulos, Antonius M. Ter Laak
  • Patent number: 6727252
    Abstract: The present invention is directed in part towards methods of modulating the function of serine/threonine protein kinases with 5-azaquinoxaline-based compounds. The methods incorporate cells that express a serine/threonine protein kinase, such as RAF. In addition, the invention describes methods of preventing and treating serine/threonine protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to 5-azaquinoxaline compounds and pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: October 16, 2000
    Date of Patent: April 27, 2004
    Assignee: Zentaris AG
    Inventors: Gerald McMahon, Heinz Weinberger, Bernhard Kutscher, Harald App
  • Patent number: 6716817
    Abstract: A method of treating female infertility using a novel cetrorelix acetate lyophilizate is disclosed.
    Type: Grant
    Filed: January 20, 1999
    Date of Patent: April 6, 2004
    Assignee: Zentaris AG
    Inventors: Jürgen Engel, Burkhard Wichert, Dieter Eauerbiar, Thomas Reissman
  • Patent number: 6706722
    Abstract: The invention relates to novel acridine derivatives of formula 1, to their preparation and to their use as medicaments, in particular for treating tumors.
    Type: Grant
    Filed: July 20, 2001
    Date of Patent: March 16, 2004
    Assignee: Zentaris AG
    Inventors: Peter Emig, Eckhard Günther, Bernd Nickel, Gerhard Bacher, Silke Baasner, Thomas Beckers, Beate Aue
  • Patent number: 6696428
    Abstract: The side effect of decrease in body weight caused by the alkylphosphocholines such as miltefosine can be antagonized by certain acetylcholine receptor antagonists such as domperidone and pimozide. The combination of alkylphosphocholine plus the antagonist does not have any effect on the anti-tumor action of the alkylphosphocholine. The combination also caused no new side effects in the animals.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: February 24, 2004
    Assignee: Zentaris AG
    Inventors: Bernd Nickel, Peter Hilgard, Thomas Klenner, Jürgen Engel
  • Patent number: 6638935
    Abstract: The invention relates to novel pyridine derivatives of formula 1, to their preparation and to their use as medicaments, in particular for treating tumors
    Type: Grant
    Filed: July 20, 2001
    Date of Patent: October 28, 2003
    Assignee: Zentaris AG
    Inventors: Peter Emig, Eckhard Günther, Bernhard Kutscher, Bernd Nickel, Jürgen Schmidt, Anita Storch
  • Patent number: 6627609
    Abstract: The invention relates to peptides which contain N-methylated amino acid units and have improved water solubility. Medicaments in which the peptides according to the invention are contained can be used for the treatment of hormone-dependent tumours and hormone-influenced non-malignant disorders.
    Type: Grant
    Filed: March 14, 2000
    Date of Patent: September 30, 2003
    Assignee: Zentaris AG
    Inventors: Michael Bernd, Bernhard Kutscher, Eckhard Günther, Peter Romeis, Thomas Reissmann, Thomas Beckers
  • Publication number: 20030181480
    Abstract: The present invention is directed in part towards methods of modulating the function of serine/threonine protein kinases with azabenzimidazole-based compounds. The methods incorporate cells that express a serine/threonine protein kinase, such as RAF. In addition, the invention describes methods of preventing and treating serine/threonine protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to azabenzimidazole compounds and pharmaceutical compositions comprising these compounds.
    Type: Application
    Filed: November 15, 2002
    Publication date: September 25, 2003
    Applicant: Zentaris AG
    Inventors: Gerald McMahon, Heinz Weinberger, Bernhard Kutscher, Harald App
  • Publication number: 20030153533
    Abstract: Novel phospholipid derivatives of the General Formula I: 1
    Type: Application
    Filed: November 8, 2002
    Publication date: August 14, 2003
    Applicant: Zentaris AG
    Inventors: Gerhard Nossner, Bernhard Kutscher, Jurgen Engel, Wolfgang Schumacher, Jurij Stekar, Peter Hilgard
  • Patent number: 6576624
    Abstract: The side effect of decrease in body weight caused by the alkylphosphocholines such as miltefosine can be antagonized by certain acetylcholine receptor antagonists such as domperidone and pimozide. The combination of alkylphosphocholine plus the antagonist does not have any effect on the anti-tumor action of the alkylphosphocholine. The combination also caused no new side effects in the animals.
    Type: Grant
    Filed: June 23, 2000
    Date of Patent: June 10, 2003
    Assignee: Zentaris AG
    Inventors: Bernd Nickel, Peter Hilgard, Thomas Klenner, Jürgen Engel
  • Patent number: 6544551
    Abstract: The present invention relates to new solid pharmaceutical compositions containing hexadecylphosphocholine (miltefosine) for oral administration in the treatment of leishmaniasis, a process for the manufacture of said pharmaceutical composition, a dosage scheme for oral administration of said pharmaceutical composition in the treatment of leishmaniasis, and finally a combination comprising said solid pharmaceutical composition, antiemeticum, and/or an antidiarrhoeal.
    Type: Grant
    Filed: July 24, 2000
    Date of Patent: April 8, 2003
    Assignee: Zentaris AG
    Inventors: Juergen Engel, Werner Sarlikiotis, Thomas Klenner, Peter Hilgard, Dieter Sauerbier, Eckhard Milsmann
  • Patent number: 6506393
    Abstract: The invention concerns a new pharmaceutical agent for oral or topical administration in the treatment of protozoal diseases, in particular of leishmaniasis, which contains as the active substance one or several compounds having the general formula I in which R1 is a saturated or monounsaturated or polyunsaturated hydrocarbon residue with 12 to 20 C atoms and R2, R3 and R4 denote independently of one another hydrogen, a C1-C5 alkyl group, a C3-C6 cycloalkyl group or a C1-C5 hydroxyalkyl group whereby two of the residues R2, R3 and R4 can together form a C2-C5 alkylene group which, if desired, can be substituted with an —O—, —S— or NR5 group, in which R5 is hydrogen, a C1-C5 alkyl group, a C3-C6 cycloalkyl group or a C1-C5 hydroxyalkyl group as well as, if desired the usual pharmaceutical auxiliary, diluting, carrier or/and filling substances.
    Type: Grant
    Filed: March 7, 2001
    Date of Patent: January 14, 2003
    Assignees: Zentaris AG, Max-Planck Gesellschaft zur Forderung der Wissenchaften e.V.
    Inventors: Hansjörg Eibl, Clemens Unger, Jürgen Engel